Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit - Akari Therapeutics (NASDAQ:AKTX)

BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory

Related Keywords

United States ,United Kingdom ,London ,City Of ,Boston ,Massachusetts ,Ray Prudo ,Eliza Schleifstein ,Mike Moyer ,Rachelle Jacques ,Exchange Commission ,Akari Therapeutics Plc ,European Commission ,Paulson Investment Company ,Akari Chairman ,American Depository Shares ,Investment Company ,Securities Act ,Orphan Drug ,Fast Track ,Rare Pediatric Disease ,Private Securities Litigation Reform Act ,Annual Report ,